High-risk neuroblastoma treatment strategy: The experience of the SIOPEN group

1 Oct

Written By Carla Aguilera

Original title: Prise en charge des neuroblastomes de haut risque : l’expérience du groupe européen SIOPEN

Valteau-Couanet D, Schleiermacher G, Sarnacki S, Pasqualini C

Bull Cancer. 2018 Oct;105(10):918-924. French. doi: 10.1016/j.bulcan.2018.09.002. Epub 2018 Oct 2. PMID: 30290975.

2018

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis